Stock Analysis
GMED (GMED) Stock Analysis
GMED (GMED) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
GMED (GMED) currently has an AIQ Score of 67/100, indicating a neutral setup. Risk is the strongest factor at 76/100. Value is the weakest current factor at 54/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
GMED at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $78.05 |
| AIQ Score | 67/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $10.85B |
| P/E Ratio (TTM) | 20.27 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $1.12 |
| Revenue (quarter ended 2026-06-30) | $789.61M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.95 |
| Volume | 1.68M |
| 52-week range | $59.51-$101.40 |
| RSI 14 | 73.49 |
| 50-Day SMA | $77.77 |
| 200-Day SMA | $83.57 |
| Analyst Price Target | — |
| Next Earnings | — |
GMED
Leader
Strong Relative Position
Latest quote
- Momentum74
- Value54
- Quality71
- Risk resilience76
- Sentiment—
GMED Stock Analysis Summary
GMED (GMED) currently has an AIQ Score of 67/100, indicating a neutral setup. Risk resilience is the strongest factor at 76/100. Value is the weakest current factor at 54/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, GMED has AIQ Score of 67/100 with Risk resilience base of 76/100 and fading Value at 54/100. Wait for component alignment before adding exposure.
Risk resilience (76/100) leads while Value (54/100) lags. This cross-factor spread creates entry timing uncertainty.
Sector · -5.86% stock move · GMED classified in its covered industry.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is GMED Bullish or Bearish Right Now?
GMED currently has a neutral overall setup. Risk Resilience is the strongest factor at 76/100, while Value is weakest at 54/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 71/100.
- - Momentum is constructive at 74/100.
- - Risk Resilience is supportive at 76/100.
- - Price is +6.61% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (36 vs 8).
- - Price is -0.79% below its 200-day SMA.
Current Consensus
GMED's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 1 neutral, and 8 sell votes. GMED's 14-day RSI is 73.49, which places the stock in an overbought momentum range. GMED's beta is 0.95, indicating market sensitivity broadly in line with the market.
What Changed in GMED?
The largest recent change in GMED is Momentum moving up by 4.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the GMED Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
GMED Decision Framework
Public evidence layers, setup checks, and risk context for GMED.
GMED (GMED) Stock Analysis
GMED has an AIQ Score of 67/100 in a Neutral regime. Risk is strongest at 76/100. Beta is not shown in the current snapshot. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | GMED is in a Neutral AIQ regime with score 67/100. |
| Signal Conflict | The primary conflict is that risk leads at 76/100 while value lags at 54/100. |
| Factor Evidence | Momentum 74/100 · Value 54/100 · Quality 71/100 · Risk 76/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 76/100.
Momentum is 74/100 and RSI (14) is 73.5.
GMED is in a Neutral regime at 67/100.
Risk factor is 76/100 and annual volatility 49.21%.
Current conflict: risk leads at 76/100 while value lags at 54/100.
GMED Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
GMED Fundamentals
GMED valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
GMED Technical Analysis
GMED technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
GMED Stock Catalysts
Track GMED earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
GMED Dividend Analysis
GMED dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
GMED Financial Data
GMED revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
GMED Risk Analysis
GMED volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
GMED Stock News
GMED stock news, market tone, recent headlines, and catalyst context.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching GMED
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for GMED
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
GMED Stock FAQ
What is GMED stock price today?
GMED's current stock price is $78.05. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is GMED bullish or bearish right now?
GMED's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is GMED's market cap?
GMED's market cap is $10.85B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is GMED's current P/E ratio?
GMED's current P/E ratio is 20.27 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is GMED's RSI?
GMED's 14-day RSI is 73.49 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is GMED above its 50-day and 200-day moving averages?
GMED is 6.61% from its 50-day SMA and -0.79% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is GMED's next earnings date?
GMED's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does GMED pay a dividend?
GMED's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.